Impact of vulvovaginal atrophy of menopause: prevalence and symptoms in Italian women according to the EVES study

on behalf of the investigators of the EVES Study

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

This cross-sectional study included postmenopausal women, aged 45–75 years, with the aim to assess the presence of vulvovaginal atrophy (VVA) confirmed by a clinical assessment in the Italian population attending menopausal/gynecological centers. Apart from baseline variables, women scored vaginal, vulvar and urinary VVA symptoms. Impact of VVA on sexual function and quality of life (QoL) was assessed thorough EuroQoL questionnaire (EQ5D3L), Day-to-Day Impact of Vaginal Aging (DIVA), Female Sexual Function Index (FSFI) and Female Sexual Distress Scale-revised (FSDS-R). A physical examination was carried out in accordance with routine gynecological practice. VVA was confirmed in 90% of the 1226 evaluable patients (aged 59.0 ± 7.3 years). The prevalence of postmenopausal women with VVA confirmed by gynecological clinical assessment was 75.3%. The patients with VVA confirmed (n = 926) had more severe symptoms (p <.0005), lower QoL (EQ-visual analog scale, p =.008 and DIVA, p <.0005) and worsened sexual function (FSFI and FSDS-R, p <.0005 for both) when compared with the patients having nonconfirmed VVA (n = 140). VVA is highly prevalent among postmenopausal Italian women. The objective of VVA confirmation is associated with severe symptoms and impaired QoL and sexual function. A proactive approach of Italian clinicians to promote regular and early gynecological evaluation should be performed in order to delay the advancing of the disorder.

Original languageEnglish
JournalGynecological Endocrinology
DOIs
Publication statusPublished - Jan 1 2019

Fingerprint

Menopause
Atrophy
Quality of Life
Visual Analog Scale
Physical Examination
Cross-Sectional Studies

Keywords

  • DIVA
  • EQ-5D
  • gynecological exam
  • prevalence
  • sexual function
  • Vulvovaginal atrophy

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Endocrinology
  • Obstetrics and Gynaecology

Cite this

Impact of vulvovaginal atrophy of menopause : prevalence and symptoms in Italian women according to the EVES study. / on behalf of the investigators of the EVES Study.

In: Gynecological Endocrinology, 01.01.2019.

Research output: Contribution to journalArticle

@article{d3960ad525b54185b526f162c537412e,
title = "Impact of vulvovaginal atrophy of menopause: prevalence and symptoms in Italian women according to the EVES study",
abstract = "This cross-sectional study included postmenopausal women, aged 45–75 years, with the aim to assess the presence of vulvovaginal atrophy (VVA) confirmed by a clinical assessment in the Italian population attending menopausal/gynecological centers. Apart from baseline variables, women scored vaginal, vulvar and urinary VVA symptoms. Impact of VVA on sexual function and quality of life (QoL) was assessed thorough EuroQoL questionnaire (EQ5D3L), Day-to-Day Impact of Vaginal Aging (DIVA), Female Sexual Function Index (FSFI) and Female Sexual Distress Scale-revised (FSDS-R). A physical examination was carried out in accordance with routine gynecological practice. VVA was confirmed in 90{\%} of the 1226 evaluable patients (aged 59.0 ± 7.3 years). The prevalence of postmenopausal women with VVA confirmed by gynecological clinical assessment was 75.3{\%}. The patients with VVA confirmed (n = 926) had more severe symptoms (p <.0005), lower QoL (EQ-visual analog scale, p =.008 and DIVA, p <.0005) and worsened sexual function (FSFI and FSDS-R, p <.0005 for both) when compared with the patients having nonconfirmed VVA (n = 140). VVA is highly prevalent among postmenopausal Italian women. The objective of VVA confirmation is associated with severe symptoms and impaired QoL and sexual function. A proactive approach of Italian clinicians to promote regular and early gynecological evaluation should be performed in order to delay the advancing of the disorder.",
keywords = "DIVA, EQ-5D, gynecological exam, prevalence, sexual function, Vulvovaginal atrophy",
author = "{on behalf of the investigators of the EVES Study} and Nappi, {R. E.} and R. Seracchioli and S. Salvatore and A. Cagnacci and {Di Paolantonio}, T. and M. Busacca",
year = "2019",
month = "1",
day = "1",
doi = "10.1080/09513590.2018.1563883",
language = "English",
journal = "Gynecological Endocrinology",
issn = "0951-3590",
publisher = "Informa Healthcare",

}

TY - JOUR

T1 - Impact of vulvovaginal atrophy of menopause

T2 - prevalence and symptoms in Italian women according to the EVES study

AU - on behalf of the investigators of the EVES Study

AU - Nappi, R. E.

AU - Seracchioli, R.

AU - Salvatore, S.

AU - Cagnacci, A.

AU - Di Paolantonio, T.

AU - Busacca, M.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - This cross-sectional study included postmenopausal women, aged 45–75 years, with the aim to assess the presence of vulvovaginal atrophy (VVA) confirmed by a clinical assessment in the Italian population attending menopausal/gynecological centers. Apart from baseline variables, women scored vaginal, vulvar and urinary VVA symptoms. Impact of VVA on sexual function and quality of life (QoL) was assessed thorough EuroQoL questionnaire (EQ5D3L), Day-to-Day Impact of Vaginal Aging (DIVA), Female Sexual Function Index (FSFI) and Female Sexual Distress Scale-revised (FSDS-R). A physical examination was carried out in accordance with routine gynecological practice. VVA was confirmed in 90% of the 1226 evaluable patients (aged 59.0 ± 7.3 years). The prevalence of postmenopausal women with VVA confirmed by gynecological clinical assessment was 75.3%. The patients with VVA confirmed (n = 926) had more severe symptoms (p <.0005), lower QoL (EQ-visual analog scale, p =.008 and DIVA, p <.0005) and worsened sexual function (FSFI and FSDS-R, p <.0005 for both) when compared with the patients having nonconfirmed VVA (n = 140). VVA is highly prevalent among postmenopausal Italian women. The objective of VVA confirmation is associated with severe symptoms and impaired QoL and sexual function. A proactive approach of Italian clinicians to promote regular and early gynecological evaluation should be performed in order to delay the advancing of the disorder.

AB - This cross-sectional study included postmenopausal women, aged 45–75 years, with the aim to assess the presence of vulvovaginal atrophy (VVA) confirmed by a clinical assessment in the Italian population attending menopausal/gynecological centers. Apart from baseline variables, women scored vaginal, vulvar and urinary VVA symptoms. Impact of VVA on sexual function and quality of life (QoL) was assessed thorough EuroQoL questionnaire (EQ5D3L), Day-to-Day Impact of Vaginal Aging (DIVA), Female Sexual Function Index (FSFI) and Female Sexual Distress Scale-revised (FSDS-R). A physical examination was carried out in accordance with routine gynecological practice. VVA was confirmed in 90% of the 1226 evaluable patients (aged 59.0 ± 7.3 years). The prevalence of postmenopausal women with VVA confirmed by gynecological clinical assessment was 75.3%. The patients with VVA confirmed (n = 926) had more severe symptoms (p <.0005), lower QoL (EQ-visual analog scale, p =.008 and DIVA, p <.0005) and worsened sexual function (FSFI and FSDS-R, p <.0005 for both) when compared with the patients having nonconfirmed VVA (n = 140). VVA is highly prevalent among postmenopausal Italian women. The objective of VVA confirmation is associated with severe symptoms and impaired QoL and sexual function. A proactive approach of Italian clinicians to promote regular and early gynecological evaluation should be performed in order to delay the advancing of the disorder.

KW - DIVA

KW - EQ-5D

KW - gynecological exam

KW - prevalence

KW - sexual function

KW - Vulvovaginal atrophy

UR - http://www.scopus.com/inward/record.url?scp=85060928348&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85060928348&partnerID=8YFLogxK

U2 - 10.1080/09513590.2018.1563883

DO - 10.1080/09513590.2018.1563883

M3 - Article

AN - SCOPUS:85060928348

JO - Gynecological Endocrinology

JF - Gynecological Endocrinology

SN - 0951-3590

ER -